Effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with Liver Cirrhosis

Simple item page
dc.contributor.authorKusnanto, P.en_US
dc.contributor.authorPrabowo, NAen_US
dc.contributor.authorBambang, Pen_US
dc.date.accessioned2019-11-25T05:24:09Z
dc.date.available2019-11-25T05:24:09Z
dc.date.issued2018-03
dc.description.abstractBackground: Cirrhosis of the liver is the liver disorder marked fibrosis and abnormal liver architecture. Treatment of liver cirrhosis, among others, is to reduce fibrogenesis. Simvastatin as an anti-fibrotic among others, by a mechanism reduce the activity of hepatic stellate cell of the liver, reduce cell proliferation liver stelat, increases the production of nitric oxide and decrease vascular resistance in the liver cirrhosis. Aim: This research to determine effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with liver cirrhosis. Methods: This study is a randomized experiment, a sample of 30 people, divided into a control group given a placebo and the treatment given simvastatin 20 mg / day orally for 4 weeks. Before and after treatment measured levels of TGF β1, FibroScan score, and a score of APRI. Statistical analysis using SPSS 22 for windows. Two different test mean using parametric tests (independent t test, paired t test) and if the data is normally distributed variable or non-parametric tests (Mann-Whitney / Wilcoxon Signed Rank Test). P significant if p <0.05. Results: The results showed that the administration of simvastatin 20 mg for 4 weeks will reduce levels TGF β1 (20,98+7,80 µg/dl pretreatment, 16,20+5,50µg/dl post treatment; p=0,013), reduce fibroscan scores (22,29+14,65 kpa pretreatment, 13,61+4,02 kpa post treatment; p=0,049) and reduce APRI scores (40,13+41,28 pretreatment, 23,41+17,61 post treatment; p=0,002). Conclusion: This study demonstrated that administration Simvastatin will be reduced levels of the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with liver cirrhosis.en_US
dc.identifier.affiliationsGastroenterohepatologi, Division of Internal Medicine Department, Medical Faculty, Universitas Sebelas Maret, Indonesiaen_US
dc.identifier.citationKusnanto P., Prabowo NA, Bambang P. Effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with Liver Cirrhosis. International Journal of Gastroenterology, Hepatology, Transplant & Nutrition. 2018 Mar; 3(1): 1-7en_US
dc.identifier.issn2455-9393
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/185187
dc.languageenen_US
dc.publisherSociety of Paediatric, Gastroenterology, Hepatobiliary, Transplant and Nutritionen_US
dc.relation.issuenumber1en_US
dc.relation.volume3en_US
dc.subjectSimvastatinen_US
dc.subjectTransforming Growth Factor β1en_US
dc.subjectFibroscan scoreen_US
dc.subjectAspartate Transaminase To Platelet Index Ratioen_US
dc.subjectLiver Cirrhosisen_US
dc.titleEffect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with Liver Cirrhosisen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijghtn2018v3n1p1.pdf
Size:
400.7 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Gastroenterology, Hepatology, Transplant & Nutrition